Abstract | OBJECTIVE: PATIENTS AND METHODS: Patients were randomly assigned to receive the following treatments: PE arm, cisplatin (50mg/m(2)) on days 1, 8, 29, and 36 and etoposide (50 mg/m(2)) on days 1-5 and 29-33 plus 60 Gy of TRT; PC arm, weekly concurrent carboplatin (AUC = 2) and paclitaxel (45 mg/m(2)) plus 60 Gy of TRT. RESULTS: A total of 65 patients were randomized (PE arm, n = 33; PC arm, n = 32). The 3-year overall survival (OS) was significantly better in the PE arm than in the PC arm (33.1% vs. 13%, P = .04). The incidence of Grade 3/4 neutropenia was 78.1% in the PE arm and 51.5% in the PC arm (P = .05). The rate of Grade 2 or greater radiation pneumonitis was 25% in the PE arm and 48.5% in the PC arm (P = .09). CONCLUSIONS: Compared to PE regimen, weekly PC regimen cannot be recommended since it failed to achieve an improvement in either OS or PFS.
|
Authors | Luhua Wang, Shixiu Wu, Guangfei Ou, Nan Bi, Wenfeng Li, Hua Ren, Jianzhong Cao, Jun Liang, Junling Li, Zongmei Zhou, Jima Lv, Xiangru Zhang |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 77
Issue 1
Pg. 89-96
(Jul 2012)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 22418243
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Etoposide
- Carboplatin
- Paclitaxel
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(mortality, pathology, therapy)
- Chemoradiotherapy
(adverse effects)
- Cisplatin
(administration & dosage)
- Disease-Free Survival
- Esophagitis
(etiology)
- Etoposide
(administration & dosage)
- Female
- Humans
- Lung Neoplasms
(mortality, pathology, therapy)
- Male
- Middle Aged
- Multivariate Analysis
- Neoplasm Staging
- Neutropenia
(etiology)
- Paclitaxel
(administration & dosage)
- Radiation Pneumonitis
(chemically induced)
- Treatment Outcome
|